¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Multiple Sclerosis, Chronic Progressive"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • multiple field irradiation
    ¿©·¯¿µ¿ªÁ¶»ç
  • multiple fission
    ¹µºÐ¿­, ´ÙÁߺп­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple infection
    º¹¼ö°¨¿°, ¿©·¯¹ø°¨¿°
  • multiple intestinal polyposis
    ´Ù¹ßÀåÆú¸³Áõ
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ, ´Ù¹ßÀåÁßøÁõ
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±Ù(À°)¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù´ë¼º¹ßÀÛ
  • multiple peripheral neuritis
    ´Ù¹ß¸»ÃʽŰ濰
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±ÙÀ°¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù°£´ë°æ·Ã
  • multiple personality
    ´ÙÁßÀΰÝ
  • multiple pregnancy
    ¹µÀÓ½Å, ´ÙÅÂÀÓ½Å
  • multiple risk
    ´ÙÁßÀ§Çèµµ
  • multiple scattering
    ´ÙÁß»ê¶õ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple stratification
    ¹µÁßÃþ
  • multiple trichoepithelioma
    ¿©·¯ÅлóÇÇÁ¾
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • multiple compressed tablet
    ´ÙÁß¾ÐÃà¾Ë¾à
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • progressive external opthalmoplegia
  • progressive facial paralysis
    ÁøÇà(¼º) ¾È¸é¸¶ºñ
  • progressive hypertrophic interstitial neuritis
    ÁøÇ༺ ºñÈļº °£Áú¼º ½Å°æ¿°(¡­ãêÌèæú).
  • progressive hypertrophic interstitial neuritis
    ÁøÇ༺ ºñÈļº °£Áú¼º ½Å°æ¿°(òäú¼àõ Ýþý§àõ ÊÖòðàõ ãêÌèæú)
  • progressive idiopathic atrophoderma
    ÁøÇ༺ ¿øÀÎºÒ¸í¼º ÇǺΠÀ§ÃàÁõ
  • progressive lenticular degeneration
    ÁøÇ༺ ·»ÁîÇÙº¯¼º(Áõ)(òäú¼àõ¡­ú·Ü¨àõ(ñø))
  • progressive lingual hemiatrophy
    ÁøÇà(¼º) ¹ÝÃø¼³À§ÃàÁõ
  • progressive lingual hemiatrophy
    ÁøÇ༺ ¹ÝÃø¼³À§ÃàÁõ(òäú¼àõ Úâö°àßê×õêñø)
  • progressive lipodystrophy
    ÁøÇ༺ Áö¹æÀÌ¿µ¾çÁõ.
  • progressive lipodystrophy
    ÁøÇ༺ Áö¹æÀÌ¿µ¾çÁõ(òäú¼àõ ò·Û¸ì¶ç½å×ñø)
  • progressive mean
    ´©°¡Æò±Õ(ËÈ˧̰˻).
  • progressive multifocal leukoencephalopathy
    ÁøÇ༺ ´Ù¹ß¼º ¹éÁú³ú(º´)Áõ
  • progressive multifocal leukoencephalopathy
    ÁøÇ༺ ´ÙÃÊÁ¡¼º ¹éÁú³úº´Áõ(òäú¼àõ Òýõ¥ïÇàõ ÛÜòõÒàÜ»ñø)
  • progressive muscle dystrophy
    ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ(òäú¼àõÐÉì¶ç½å×ñø).
  • progressive muscle dystrophy
    ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ(òäú¼àõ ì¶ç½å×ñø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
CIDP chronic idiopathic polyradiculopathy; chronic inflammatory demyelinating polyradiculoneuropathy
CIP chronic idiopathic polyradiculoneuropathy; chronic intestinal pseudo-obstruction; Collection de l'In...
CLD chloride diarrhea; chronic liver disease; chronic lung disease; congenital limb deficiency; crystal ...
CLL cholesterol-lowering lipid; chronic lymphatic leukemia; chronic lymphocytic leukemia; cow lung lavag...
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PMR Progressive Muscle Relaxation
PME Progressive Myoclonus Epilepsy
PR Progressive Ratio
PSP Progressive supranuclear paly
PSS Progressive Systemic Scleroderma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chronic diffuse sclerosing osteomyelitis
    ¸¸¼º ¹Ì¸¸¼º °æÈ­¼º °ñ¼ö¿°
    ¹Ì¸¸¼ºÀÇ Ä¡ÃßÁúȯ¿¡ ÀÇÇÑ °¨¿°¿¡¼­ ºñ·ÔµÈ´Ù. ³·Àº Á¤µµÀÇ °¨¿°¿¡ ´ëÇÑ °ñÀÇ Áõ½Ä¼º ¹ÝÀÀÀÌ´Ù. ³ë³âÃþÀÇ ¹«Ä¡¾Ç ºÎÀ§¿¡ ÁÖ·Î »ý±ä´Ù. Ưº°ÇÑ ¼Ò°ßÀº ¾ø´Ù. °ñÀÇ ¹Ì¸¸¼º °æÈ­°¡ ½ÉÇÏ°í ¾çÃø¼ºÀÌ´Ù. °æ°è´Â ºÒ¸í·áÇÏ´Ù. Á¶Á÷º´¸®ÇÐÀû ¼Ò°ßÀº Á¶¹ÐÇÏ°í ºÒ±ÔÄ¢ÇÑ °ñ¼ö, ¼¶À¯¼º °ñ¼ö°­ÀÌ´Ù.
  • chronic disease
    ¸¸¼º Áúȯ
    º´ÀÇ °æ°úÀÇ Àå´Ü¿¡ ÀÇÇÑ ºÐ·ù. º¸Åë 6°³¿ù ȤÀº l³â ÀÌ»ó °è¼ÓµÇ´Â ÁúȯÀ» ¸»Çϸç, ±Þ¼º Áúȯ°ú ´ëÀÀÇÑ´Ù. ±× Áõ¼¼°¡ ¿Ï¸¸ÇÏ°Ô ³ªÅ¸³ª Àå±â°£ Áö¼ÓÇϹǷΠ¸¸¼º Áõ»óÀ̶ó Çϸç, À̰͵µ ±Þ¼º Áúȯ¿¡¼­ÀÇ ±Þ¼º Áõ»ó¿¡ ´ëÀÀÇÏ´Â ¸»ÀÌ´Ù. ´ëÇ¥ÀûÀÎ ¸¸¼º ÁúÇÑÀ¸·Î´Â °áÇÙ, ³ªº´, ¸Åµ¶ µîÀÌ ÀÖ°í, ±Þ¼º Áúȯ¿¡¼­ ÀÌÇàÇÏ´Â °Íµµ ¸¹´Ù. ´Ü¼øÈ÷ ¾ËÄÚ¿Ã Áßµ¶À̳ª °üÀý ·ù¸ÓƼÁò µîÀÇ °æ¿ì´Â ¸¸¼ºÀ¸·Î º¸´Â °æ¿ì°¡ ¸¹´Ù.
  • chronic empyema
    ¸¸¼º ³óÈä
  • chronic endemic dental fluorosis
    ¸¸¼º À¯Ç༺ Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ, ¸¸¼º dzÅ伺 Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ
  • chronic erythematous atrophic candidosis
    ¸¸¼º È«¹Ý¼º À§Ã༺ ĵµð´ÙÁõ
  • chronic exposure
    ¸¸¼º ³ëÃâ
  • chronic factitious disorder with physical symptom
    ¸¸¼º ÀΰøÀû Àå¾Ö ½ÅüÀû
  • chronic fatigue syndrome
    ¸¸¼º ÇÇ·Î ÁõÈıº
    ½±°Ô ÇǰïÇϰí ÁöÄ¡¸ç ¸öÀÌ ³ª¸¥ÇØÁö´Â µîÀÇ ÇÇ·Î Áõ¼¼°¡ 6°³¿ù ÀÌ»ó ¸¸¼ºÀûÀ¸·Î Áö¼ÓÇÏ´Â Áõ»ó. È®½ÇÇÑ ¿øÀÎÀº ¹àÇôÁ® ÀÖÁö ¾Ê°í, ¹ÙÀÌ·¯½º °¨¿°ÀÌ ±× ¿øÀÎÀÇ Çϳª·Î ÃßÁ¤µÈ´Ù. Æò¼Ò °Ç°­ÇÑ »ç¶÷¿¡°Ô¼­ °¨±â³ª ¸ö»ì ±â¿îÀÌ ÀÖ´Ù°¡ ÀÌ·± ÇǷΰ¡ ³ªÅ¸³­´Ù. ´ëü·Î Ưº°ÇÑ Ä¡·á°¡ ÇÊ¿ä¾øÀÌ ÀúÀý·Î Ä¡À¯µÇ³ª ÇǷθ¦ ´À³¢°Ô ÇÏ´Â ´Ù¸¥ Áúº´ÀÇ À¯¹«¸¦ È®ÀÎÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. ƯÈ÷ ½ºÆ®·¹½º, ¿ì¿ïÁõ, ºÒ¾ÈÀå¾Ö µî°ú °°Àº Á¤½ÅÀû ¹®Á¦°¡ ¾à 50 %¸¦ Â÷ÁöÇϸç, ½ÅüÀû ÁúȯÀ¸·Î´Â ´ç´¢º´, °©»ó¼± Áúȯ, ¸¸¼º È£Èí±â Áúȯ, ºóÇ÷, °áÇÙ, °£¿°, ½ÅÀå ÁúȯÀ̳ª ¾Ï µî¿¡ ÀÇÇØ¼­µµ ¸¸¼ºÀû ÇǷΰ¨À» ´À³¥ ¼ö ÀÖ´Ù. ÀÌ¿Í °°Àº ÁúȯÀÌ ¾ø´Â °ÍÀÌ ÆÇ¸íµÇ¸é ¸¸¼º ÇÇ·Î ÁõÈıºÀ¸·Î Áø´ÜÇÒ ¼ö ÀÖ´Ù.
  • chronic flying sickness
    ¸¸¼º Ç×°øº´
    Àå±â°£ Ç×°ø±â¿¡ ž½ÂÇÏ´Â »ç¶÷¿¡°Ô ÀϾ´Â Á÷¾÷º´. Ç×°ø±âÀÇ ²÷ÀÓ¾ø´Â µ¿¿ä, ¼±È¸, °¡¼Óµµ, °í°ø ºñÇàÀ¸·ÎºÎÅÍ ¿À´Â »ê¼ÒÀÇ ºÎÁ·, ±â¾ÐÀÌ ³·Àº °í°øÀ» ºñÇàÇϰųª Àú¾Ð½Ç¿¡¼­ ÀÛ¾÷À» ÇÏ´Â °æ¿ì, ±×°ÍÀ¸·Î ±Þ¼º ÁúȯÀÌ ÀϾÁö ¾Ê´Â Á¤µµÀÇ È¯°æÀÌ Àå±â°£¿¡ °ÉÃļ­ µÇÇ®ÀÌµÉ ¶§ ¹ß»ýÇϱ⠽±´Ù. Áõ¼¼´Â Ãʱ⿡ ´«ÀÇ ÇÇ·Î, µÎÅë, ÇǷΰ¨ µîÀÇ ÀÚ°¢ Áõ¼¼°¡ ÀϾ°í, ÀÌ¿Í °°Àº ´Ü°è°¡ Áö³ª¸é ÃÊÁ¶°¨, ½Å°æÁú, ºÒ¸éÁõ, ±â¾ï·Â, ÁýÁß·ÂÀÇ °¨Åð¿Í ÇÔ²² ±¸Åä, Çö±âÁõ, ¼ÒÈ­ºÒ·® µîÀÌ ÀϾ´Ù. À̰ÍÀº °í°ø ºñÇàÀ̳ª, ¼Óµµ°¡ ºü¸£°í ¼±È¸°¡ ½ÉÇÑ ÀüÅõ±â¸¦ Á¶Á¾ÇÏ´Â ÀüÅõ Á¶Á¾»ç¿¡°Ô ¹ß»ýµÇ´Â °æ¿ì°¡ ¸¹´Ù.
  • chronic gingivitis
    ¸¸¼º Ä¡Àº¿°
    1. º¯¿¬ Ä¡ÀºÀÇ ºÎÁ¾, ÃâÇ÷À» º¸ÀδÙ. È­³ó¼ºÀ̸ç, Ä¡ÀºÀÇ Á¡¸ôÀÌ ¼Ò½ÇµÈ´Ù. ±¹¼ÒÀûÀÌ ¿äÀÎÀ¸·Î´Â ¹Ì»ý¹°, À½½Ä¹° ¾ÐÀÔ, ºÎÀûÀýÇÑ º¸Á¸ óġ³ª º¸Ã¶¹°, ±¸È£Èí, Ä¡¾ÆÀÇ À§Ä¡ ÀÌ»ó, È­Çй°Áú ȤÀº ¾à¹° º¹¿ëÀÌ ÀÖÀ¸¸ç, Àü½ÅÀûÀÎ ¿äÀÎÀ¸·Î´Â ¿µ¾ç Àå¾Ö, ¾à¸® ÀÛ¿ë, ÀÓ½Å, ´ç´¢, ¾Ë·¯Áö, À¯Àü, Á¤½Å Áúȯ µîÀÌ ÀÖ´Ù. 2. Ä¡ÀºÀÌ Àü¹ÝÀûÀ¸·Î â¹éÇÏ°í ¼¶À¯¼º ¿Ü°üÀ» °¡Áö´Â ¿­±¸ ¸é°ú Ä¡°£ À¯µÎÀÇ ¿°ÁõÀÌ´Ù. Ä¡Àº À¯µÎÀÇ ¼Ò½Ç°ú °°Àº Ä¡ÀºÀÇ ¿ÜÇü º¯È­µµ ÀϾ ¼ö ÀÖ´Ù. À̰ÍÀº ¼ö³â°£ÀÇ ¿°Áõ¼º Ä¡Àº ¼Õ»ó¿¡ ´ëÇÑ ¸¸¼ºÀû ¼øÈ¯Àû º¹±¸ ¹ÝÀÀÀ̸ç Ä¡ÁÖ¿°ÀÇ Æ¯Â¡°ú ¿¬°üµÉ ¶§°¡ ÀÖ´Ù.
  • chronic granulocytic leukemia
    ¸¸¼º °ú¸³±¸ ¹éÇ÷º´, ¸¸¼º °ú¸³±¸¼º ¹éÇ÷º´
  • chronic headache
    ¸¸¼º µÎÅë
  • chronic hemorrhage
    ¸¸¼º ÃâÇ÷
  • chronic hepatitis B
    ¸¸¼º BÇü °£¿°
  • chronic hyperplastic gingivitis
    ¸¸¼º Áõ½Ä¼º Ä¡Àº¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
multiple anchorage Anchorage in which more than one type of resistance unit is utilised.
Synonym: reinforced anchorage.
(05 Mar 2000)
multiple birth offspring The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc.
(12 Dec 1998)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á